FOLH1 and prostate carcinoma: Clinically approved targeted therapies for prostate cancer comprise various PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) and the PSMA-targeted radioligand therapy lutetium (177Lu) vipivotide tetraxetan (Lu-PSMA).